Cambridge's Akcea discloses layoffs after FDA drug rejection

Cambridge-based Akcea Therapeutics Inc. said Thursday that it plans to lay off 10 percent of its workforce following the FDA's rejection of its rare disease drug last week. While Akcea (Nasdaq: AKCA) did not say how many people would be laid off, the company told the Business Journal in June that it had more than 200 employees. That suggests the cuts will affect around 20 workers. The layoffs were disclosed in a filing with the U.S. Securities and Exchange Commissio n. In a statement, Akcea said…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news